TRimetazidine for acUte on Chronic Liver Failure STudy (TRUST)

A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure

The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.

Study Overview

• Status: Suspended
• Conditions: Acute-On-Chronic Liver Failure
• Intervention / Treatment: Drug: Trimetazidine

Detailed Description

The study will assess the PK, tolerability, and safety of oral trimetazidine administered to subjects with acute-on-chronic (ACLF) Grades 1 and 2 with liver failure and a range of renal function. Subjects will receive up to 60 mg/day for 28 days.

Two groups of subjects will be enrolled:

Group 1

• AD with serum creatinine ≥ 1 and < 2 mg/dL, OR

• ACLF 1 with

  • liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
  • liver failure and West Haven grade 1-2 hepatic encephalopathy, or
  • coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
  • coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR

• ACLF 2 with

  • liver failure and coagulation failure, or
  • liver failure and West Haven grade 3-4 hepatic encephalopathy.

Group 2

• ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR

• ACLF 2 with

  • liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or
  • coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL).

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• Austria
  • Graz, Austria
    • Medical University of Graz
  • Innsbruck, Austria
    • Medical University of Innsbruck
  • Vienna, Austria
    • Medical University of Vienna
• Belgium
  • Antwerp, Belgium
    • University of Antwerp
  • Brussels, Belgium
    • Erasme hospital
• France
  • Lille, France
    • Hospital Claude Huriez
  • Paris, France
    • Hospital Pitie-Salpetriere
  • Rennes, France
    • Rennes University Hospital
  • Villejuif, France
    • Hopital Paul Brousse
• Germany
  • Essen, Germany
    • University of Essen
  • Frankfurt, Germany
    • JW Goethe Clinic
  • Halle, Germany
    • Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin I
  • Hannover, Germany
    • University of Hannover
  • Heidelberg, Germany
    • University of Heidelberg
  • Leipzig, Germany
    • University of Leipzig
  • Münster, Germany
    • University of Munster
• Spain
  • Barcelona, Spain
    • Hospital Clínic
  • Barcelona, Spain
    • Hospital Valle de Hebron
  • Córdoba, Spain
    • Hospital Reina Sofia
  • Madrid, Spain
    • Hospital Ramon y Cajal
  • Madrid, Spain
    • Hospital Gregorio Marañón
  • Madrid, Spain
    • Hospital Puerta de Hierro
  • Santander, Spain
    • Hospital Marques de Valdecilla Santander
  • Seville, Spain
    • Hospital Virgen del Rocío

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 18 to 75 years, inclusive, at screening.
2. Stable diagnosis of AD, ACLF Grade 1 or ACLF Grade 2 for no less than 2 days (as determined at the discretion of the investigator)*.
3. Anticipated duration of hospital stay of at least 7 days.

4. For Group 1:

   • AD with SCr ≥ 1 and < 2 mg/dL, OR

   • ACLF 1 with

     • Tbil ≥ 12 mg/dL, SCr ≥ 1.5 and < 2 mg/dl, and HE 0-2, or
     • Tbil ≥ 12 mg/dL, and SCr < 1.5 mg/dL, and HE 1-2, or
     • INR ≥ 2.5, SCr ≥ 1.5 and < 2 mg/dl, and HE 0-2, or
     • INR ≥ 2.5, SCr < 1.5 mg/dL, and HE 1-2, OR

   • ACLF 2 with

     • Tbil ≥ 12 mg/dL, INR ≥ 2.5, and SCr < 2 mg/dL, or
     • Tbil ≥ 12 mg/dL, HE 3-4, and SCr < 2 mg/dL

5. For Group 2:

   • ACLF 1 with SCr ≥ 2.0 and < 3.5 mg/dL, OR

   • ACLF 2 with

     • Tbil ≥ 12 mg/dL, and SCr ≥ 2 and < 3.5 mg/dL, or
     • INR ≥ 2.5, and SCr ≥ 2 and < 3.5 mg/dL.
6. Female patients must be of non-childbearing potential, or, if non-sterile, must agree to sexual abstinence or use a highly effective method of contraception from Screening to 3 days after the final dose.
7. Non sterile male patients must agree to sexual abstinence or use a highly effective method of contraception from Screening to 3 days after the final dose if sexually active.
8. Able to comprehend and willing to sign an informed consent form, or, if unable to consent, consent is conducted per local requirements.

Exclusion Criteria:

1. Diagnosis of AD or ACLF (of any grade) >14 days before enrollment*.
2. Circulatory failure.
3. Respiratory failure i.e. PaO2/FiO2 ≤ 200 and/or baseline SpO2/FiO2 ≤ 214.
4. Brain failure (West Haven grade 3 or 4 hepatic encephalopathy) with coagulation failure (INR > 2.5).
5. Gastrointestinal bleeding within 72 hours prior to enrollment. (Subjects who fail this criterion may qualify after 72 hours).
6. Uncontrolled bacterial infection (urinary tract infection, spontaneous bacterial peritonitis, pneumonia, bacteremia, soft tissue infections, etc.) (as determined at the discretion of the investigator).
7. Invasive fungal infection.
8. Platelet count <30,000 cells/mL.
9. White blood cell count <1000 cells/uL.
10. Patients on hemodialysis or continuous venovenous hemofiltration.
11. Patients who have undergone or are scheduled for imminent organ transplantation. (Patients may be on a transplant list as long as no date has been set for transplantation)
12. Hospitalization for ACLF within the 3 months prior to screening.
13. History of hepatocellular carcinoma, unless within Milan Criteria (up to 3 lesions each < 3 cm or 1 lesion < 5 cm; no extrahepatic involvement; no evidence of gross vascular invasion).
14. Active non-hepatic malignancy.
15. Parkinson's disease, Parkinsonian-type symptoms (gait disorder, tremor, etc.), restless leg syndrome or other movement disorders other than asterixis.
16. Fulminant Wilson's, fulminant autoimmune hepatitis, or Budd-Chiari syndrome.
17. Septic shock (hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L (> 18 mg/dL) after adequate fluid resuscitation.
18. Patients who have undergone placement of a transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt in the past 6 months.
19. Any invasive procedure within 48 hours prior to enrollment with high risk of uncontrolled bleeding (as determined at the discretion of the investigator).
20. Female with a positive pregnancy test or lactating.
21. Positive results for human immunodeficiency virus HIV-1 or HIV-2.
22. Current treatment with trimetazidine.
23. Known allergy to trimetazidine or excipients.
24. Currently receiving an investigational treatment.
25. Any condition that, in the opinion of the Investigator (or designee), would limit the subject's ability to complete or participate in this clinical study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: NON_RANDOMIZED
• Interventional Model: SEQUENTIAL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Group 1; AD with serum creatinine ≥ 1 and < 2 mg/dL, OR; ACLF 1 withliver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, orliver failure and West Haven grade 1-2 hepatic encephalopathy, orcoagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, orcoagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR; ACLF 2 withliver failure and coagulation failure, orliver failure and West Haven grade 3-4 hepatic encephalopathy.	Drug: Trimetazidine; Subjects with receive up to 60 mg daily
EXPERIMENTAL: Group 2; ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR; ACLF 2 withliver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), orcoagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL).	Drug: Trimetazidine; Subjects with receive up to 60 mg daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
plasma pharmacokinetics	Cmax	28 days
plasma pharmacokinetics	AUC	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of treatment-emergent adverse events [Safety and Tolerability]	Adverse events	90 days

Collaborators and Investigators

• Sponsor: Martin Pharmaceuticals
• Investigators: Study Director: Chief Medical Officer, Martin Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (ACTUAL): November 28, 2018
• Primary Completion (ANTICIPATED): June 30, 2021
• Study Completion (ANTICIPATED): June 30, 2021

Study Registration Dates

• First Submitted: November 7, 2018
• First Submitted That Met QC Criteria: November 7, 2018
• First Posted (ACTUAL): November 9, 2018

Study Record Updates

• Last Update Posted (ACTUAL): March 4, 2021
• Last Update Submitted That Met QC Criteria: March 2, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Liver Failure, Acute; End Stage Liver Disease; Liver Failure; Hepatic Insufficiency; Acute-On-Chronic Liver Failure; Vasodilator Agents; Trimetazidine
• Other Study ID Numbers: MP-0614-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No